Research ArticleMetabolism, Transport, and Pharmacogenomics
Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors
Julie-Anne Tanner, Bhagwat Prasad, Katrina G. Claw, Patricia Stapleton, Amarjit Chaudhry, Erin G. Schuetz, Kenneth E. Thummel and Rachel F. Tyndale
Journal of Pharmacology and Experimental Therapeutics January 2017, 360 (1) 129-139; DOI: https://doi.org/10.1124/jpet.116.237594
Julie-Anne Tanner
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada (J-A.T., R.F.T.); Department of Pharmacology and Toxicology (J-A.T., R.F.T.) and Department of Psychiatry (R.F.T.), University of Toronto, Toronto, Ontario, Canada; Department of Pharmaceutics (B.P., K.G.C, K.E.T.) and Center for Exposures, Diseases, Genomics, and Environment (P.S.), University of Washington, Seattle, Washington; Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee (A.C., E.G.S.)
Bhagwat Prasad
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada (J-A.T., R.F.T.); Department of Pharmacology and Toxicology (J-A.T., R.F.T.) and Department of Psychiatry (R.F.T.), University of Toronto, Toronto, Ontario, Canada; Department of Pharmaceutics (B.P., K.G.C, K.E.T.) and Center for Exposures, Diseases, Genomics, and Environment (P.S.), University of Washington, Seattle, Washington; Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee (A.C., E.G.S.)
Katrina G. Claw
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada (J-A.T., R.F.T.); Department of Pharmacology and Toxicology (J-A.T., R.F.T.) and Department of Psychiatry (R.F.T.), University of Toronto, Toronto, Ontario, Canada; Department of Pharmaceutics (B.P., K.G.C, K.E.T.) and Center for Exposures, Diseases, Genomics, and Environment (P.S.), University of Washington, Seattle, Washington; Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee (A.C., E.G.S.)
Patricia Stapleton
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada (J-A.T., R.F.T.); Department of Pharmacology and Toxicology (J-A.T., R.F.T.) and Department of Psychiatry (R.F.T.), University of Toronto, Toronto, Ontario, Canada; Department of Pharmaceutics (B.P., K.G.C, K.E.T.) and Center for Exposures, Diseases, Genomics, and Environment (P.S.), University of Washington, Seattle, Washington; Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee (A.C., E.G.S.)
Amarjit Chaudhry
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada (J-A.T., R.F.T.); Department of Pharmacology and Toxicology (J-A.T., R.F.T.) and Department of Psychiatry (R.F.T.), University of Toronto, Toronto, Ontario, Canada; Department of Pharmaceutics (B.P., K.G.C, K.E.T.) and Center for Exposures, Diseases, Genomics, and Environment (P.S.), University of Washington, Seattle, Washington; Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee (A.C., E.G.S.)
Erin G. Schuetz
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada (J-A.T., R.F.T.); Department of Pharmacology and Toxicology (J-A.T., R.F.T.) and Department of Psychiatry (R.F.T.), University of Toronto, Toronto, Ontario, Canada; Department of Pharmaceutics (B.P., K.G.C, K.E.T.) and Center for Exposures, Diseases, Genomics, and Environment (P.S.), University of Washington, Seattle, Washington; Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee (A.C., E.G.S.)
Kenneth E. Thummel
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada (J-A.T., R.F.T.); Department of Pharmacology and Toxicology (J-A.T., R.F.T.) and Department of Psychiatry (R.F.T.), University of Toronto, Toronto, Ontario, Canada; Department of Pharmaceutics (B.P., K.G.C, K.E.T.) and Center for Exposures, Diseases, Genomics, and Environment (P.S.), University of Washington, Seattle, Washington; Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee (A.C., E.G.S.)
Rachel F. Tyndale
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada (J-A.T., R.F.T.); Department of Pharmacology and Toxicology (J-A.T., R.F.T.) and Department of Psychiatry (R.F.T.), University of Toronto, Toronto, Ontario, Canada; Department of Pharmaceutics (B.P., K.G.C, K.E.T.) and Center for Exposures, Diseases, Genomics, and Environment (P.S.), University of Washington, Seattle, Washington; Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee (A.C., E.G.S.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleMetabolism, Transport, and Pharmacogenomics
Impact of Genetic and Nongenetic Factors on CYP2A6
Julie-Anne Tanner, Bhagwat Prasad, Katrina G. Claw, Patricia Stapleton, Amarjit Chaudhry, Erin G. Schuetz, Kenneth E. Thummel and Rachel F. Tyndale
Journal of Pharmacology and Experimental Therapeutics January 1, 2017, 360 (1) 129-139; DOI: https://doi.org/10.1124/jpet.116.237594
Research ArticleMetabolism, Transport, and Pharmacogenomics
Impact of Genetic and Nongenetic Factors on CYP2A6
Julie-Anne Tanner, Bhagwat Prasad, Katrina G. Claw, Patricia Stapleton, Amarjit Chaudhry, Erin G. Schuetz, Kenneth E. Thummel and Rachel F. Tyndale
Journal of Pharmacology and Experimental Therapeutics January 1, 2017, 360 (1) 129-139; DOI: https://doi.org/10.1124/jpet.116.237594
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement